Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations
Tian‐Hua Wei, Zixuan Wang, Meng‐Yi Lu, Yujing Xu, Jin Yang, Xing-Feng Ni, Cheng Yang, Mengyuan Zhang, Jia‐Chuan Liu, Qingqing Li, Jiao Cai, Zijun Chen, Ji-Bo Kang, Nan Li, Nan Li, Wei‐Chen Dai, Ning Ding, Yan‐Cheng Yu, Xuejiao Leng, Xin Xue, Xiao-Long Wang, Shan‐Liang Sun, Ye Yang, Nian‐Guang Li, Nian‐Guang Li, Zhi‐Hao Shi
Abstract
The FLT3-ITD (internal tandem duplication) mutant has been a promising target for acute myeloid leukemia (AML) drug discovery but is now facing the challenge of resistance due to point mutations. Herein, we have discovered a type II FLT3 inhibitor, SILA-123 . This inhibitor has shown highly potent inhibitory effects against FLT3-WT (IC 50 = 2.1 nM) and FLT3-ITD (IC 50 = 1.0 nM), tumor cells with the FLT3-ITD mutant such as MOLM-13 (IC 50 = 0.98 nM) and MV4-11 (IC 50 = 0.19 nM), as well as BaF3 cells associated with the FLT3-ITD mutant and point mutations like BaF3-FLT3-ITD-G697R (IC 50 = 3.0 nM). Moreover, SILA-123 exhibited promising kinome selectivity against 310 kinases (S score (10) = 0.06). In in vivo studies, SILA-123 significantly suppressed the tumor growth in MV4-11 (50 mg/kg/d, TGI = 87.3%) and BaF3-FLT3-ITD-G697R (50 mg/kg/d, TGI = 60.0%) cell-inoculated allograft models. Our data suggested that SILA-123 might be a promising drug candidate for FLT3-ITD-positive AML.